QPS Implements LabLogic's DEBRA LIMS
News Sep 10, 2013
QPS has now fully validated LabLogic Debra version 6.0.6 for use in radiolabeled metabolism studies. An earlier version was implemented in 2010 to support discovery stage radiolabel ADME studies. The implementation of Debra LIMS coupled with the recent addition of a high resolution mass spectrometer (HRMS) ensures rapid integration of radioactivity data from mass balance excretion and/or quantitative whole-body autoradiography (QWBA) studies with metabolite identification and radio-quantitation to shorten timelines in support of preclinical and human mass balance studies.
Huw Loaring, PhD., LabLogic’s Systems Director said “There are currently seven sites who have upgraded to Debra 6 and we are very pleased to have worked closely with QPS developing custom-made test scripts for them. QPS is our first contract laboratory to be using this latest release in a fully validated environment.”
Zamas Lam, Ph.D., Senior Vice President & Global Head of Pre-Clinical Development, states “Implementation of a fully validated LIMS will further guarantee data quality, improve efficiency, and provide additional flexibility. As a world class DMPK service provider this type of continuous improvement initiative is paramount to providing unparalleled services to our world-wide customers.”
Getting to Know the Microbes that Drive Climate ChangeNews
A new understanding of the microbes and viruses in the thawing permafrost in Sweden may help scientists better predict the pace of climate change.READ MORE
How Many People Die From TB Every Year?News
Discrepancies between the estimates for global tuberculosis deaths is due to different methodologies and data sources used by each institution. The results highlight the need to improve the modeling approaches in these countries in order to understand the true burden of the disease and design adequate health policies.READ MORE
ExPecto Patronum! Magical Machine Learning Tool Summons DNA Dark Matter DataNews
A new machine learning framework, dubbed ExPecto, can predict the effects of mutations in the so-called “dark matter” regions of the human genome. ExPecto pinpoints how mutations can disrupt the way genes turn on and off throughout your body.